Demonstrating clinical benefit is the ultimate gateway to smoother patient access. When health plan and pharmacy benefit manager (PBM) clinical decision-makers review a Phase II or Phase III product ...
Full results published in the New England Journal of Medicine and presented at ATS 2025 International Conference BATURA builds upon the previous Phase III MANDALA and DENALI trials and in totality, ...
FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8 Biomarker improvements are strongly associated with longer survival, ...
SAN DIEGO, CA / ACCESS Newswire / April 15, 2025 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of ...
The First Phase III Study Testing Ivonescimab Now Represents the First Statistically Significant OS Benefit Achieved by an Ivonescimab-Containing Regimen Ivonescimab Plus Chemotherapy Demonstrates ...
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) ...
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today noted that our partner, Akeso, Inc. (“Akeso,” HKEX Code: 9926.HK) published results from the Phase III HARMONi-A trial, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results